Enavatuzumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Enavatuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target TWEAK receptor
Clinical data
Legal status
?
Identifiers
CAS number 912628-39-8 N
ATC code None
Chemical data
Formula C6334H9792N1700O2000S42 
Mol. mass 143.1 kDa
 N (what is this?)  (verify)

Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors.

Enavatuzumab was developed by Facet Biotech Corp.[1]

References[edit]

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Enavatuzumab". American Medical Association.